Which has preferable valuation & earnings, RNA or REPL?

Replimune Group has lower revenue, but higher earnings than Avidity Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avidity Biosciences $36.68M 5.83 -$322.30M N/A N/A Replimune Group N/A N/A -$247.30M -$3.44 N/A

Which has better earnings & valuation, RNA or ORIC?

Oric Pharmaceuticals has lower revenue, but higher earnings than Avidity Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avidity Biosciences $36.68M 5.83 -$322.30M N/A N/A Oric Pharmaceuticals N/A N/A -$129.47M -$1.44 N/A

Does the media refer more to RNA or ORIC?

In the previous week, Oric Pharmaceuticals had 3 more articles in the media than Avidity Biosciences. MarketBeat recorded 5 mentions for Oric Pharmaceuticals and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.11 beat Oric Pharmaceuticals' score of 0.59 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oric Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, RNA or KURA?

Kura Oncology has higher revenue and earnings than Avidity Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avidity Biosciences $36.68M 5.83 -$322.30M N/A N/A Kura Oncology $67.48M 12.12 -$278.67M -$3.35 N/A

Does the media prefer RNA or KURA?

In the previous week, Kura Oncology had 6 more articles in the media than Avidity Biosciences. MarketBeat recorded 8 mentions for Kura Oncology and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.11 beat Kura Oncology's score of 0.61 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, RNA or SANA?

Sana Biotechnology has lower revenue, but higher earnings than Avidity Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avidity Biosciences $36.68M 5.83 -$322.30M N/A N/A Sana Biotechnology N/A N/A -$244.17M -$0.93 N/A

Does the media favor RNA or SANA?

In the previous week, Sana Biotechnology had 2 more articles in the media than Avidity Biosciences. MarketBeat recorded 4 mentions for Sana Biotechnology and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.11 beat Sana Biotechnology's score of 0.47 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sana Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, EVMN or RNA?

Evommune has higher earnings, but lower revenue than Avidity Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evommune $13M 55.75 -$68.87M -$9.50 N/A Avidity Biosciences $36.68M 5.83 -$322.30M N/A N/A

Does the media favor EVMN or RNA?

In the previous week, Avidity Biosciences had 1 more articles in the media than Evommune. MarketBeat recorded 2 mentions for Avidity Biosciences and 1 mentions for Evommune. Avidity Biosciences' average media sentiment score of 1.11 beat Evommune's score of -0.35 indicating that Avidity Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Avidity Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Avidity Biosciences (RNA) Competitors

$12.50 -0.25 (-1.96%)

As of 10:27 AM Eastern

Compare

RNA vs. REPL, ORIC, KURA, SANA, and EVMN

Should you buy Avidity Biosciences stock or one of its competitors? MarketBeat compares Avidity Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avidity Biosciences include Replimune Group (REPL), Oric Pharmaceuticals (ORIC), Kura Oncology (KURA), Sana Biotechnology (SANA), and Evommune (EVMN). These companies are all part of the "pharmaceutical products" industry.

How does Avidity Biosciences compare to Replimune Group?

Avidity Biosciences (NASDAQ:RNA) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, Avidity Biosciences had 1 more articles in the media than Replimune Group. MarketBeat recorded 2 mentions for Avidity Biosciences and 1 mentions for Replimune Group. Replimune Group's average media sentiment score of 1.89 beat Avidity Biosciences' score of 1.11 indicating that Replimune Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Avidity Biosciences	Positive
Replimune Group	Very Positive

Replimune Group has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Avidity Biosciences' return on equity of -44.92% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%
Replimune Group	N/A	-102.69%	-72.22%

Replimune Group has lower revenue, but higher earnings than Avidity Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$36.68M	5.83	-$322.30M	N/A	N/A
Replimune Group	N/A	N/A	-$247.30M	-$3.44	N/A

Avidity Biosciences currently has a consensus target price of $70.29, suggesting a potential upside of 462.35%. Replimune Group has a consensus target price of $4.88, suggesting a potential downside of 43.77%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Avidity Biosciences is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.33
Replimune Group	3 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.70

92.5% of Replimune Group shares are held by institutional investors. 3.8% of Avidity Biosciences shares are held by insiders. Comparatively, 5.2% of Replimune Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Avidity Biosciences has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Replimune Group has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

Summary

Avidity Biosciences beats Replimune Group on 10 of the 15 factors compared between the two stocks.

How does Avidity Biosciences compare to Oric Pharmaceuticals?

Avidity Biosciences (NASDAQ:RNA) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 3.8% of Avidity Biosciences shares are owned by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Oric Pharmaceuticals has lower revenue, but higher earnings than Avidity Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$36.68M	5.83	-$322.30M	N/A	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A

Avidity Biosciences presently has a consensus price target of $70.29, indicating a potential upside of 462.35%. Oric Pharmaceuticals has a consensus price target of $18.92, indicating a potential upside of 133.02%. Given Avidity Biosciences' higher possible upside, equities research analysts plainly believe Avidity Biosciences is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.33
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

In the previous week, Oric Pharmaceuticals had 3 more articles in the media than Avidity Biosciences. MarketBeat recorded 5 mentions for Oric Pharmaceuticals and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.11 beat Oric Pharmaceuticals' score of 0.59 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oric Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oric Pharmaceuticals has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Oric Pharmaceuticals' return on equity of -35.33% beat Avidity Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%
Oric Pharmaceuticals	N/A	-35.33%	-33.31%

Avidity Biosciences has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

Summary

Oric Pharmaceuticals beats Avidity Biosciences on 10 of the 15 factors compared between the two stocks.

How does Avidity Biosciences compare to Kura Oncology?

Avidity Biosciences (NASDAQ:RNA) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Avidity Biosciences presently has a consensus price target of $70.29, suggesting a potential upside of 462.35%. Kura Oncology has a consensus price target of $25.46, suggesting a potential upside of 176.28%. Given Avidity Biosciences' higher probable upside, equities analysts plainly believe Avidity Biosciences is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.33
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Avidity Biosciences has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

In the previous week, Kura Oncology had 6 more articles in the media than Avidity Biosciences. MarketBeat recorded 8 mentions for Kura Oncology and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.11 beat Kura Oncology's score of 0.61 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kura Oncology has a net margin of -411.19% compared to Avidity Biosciences' net margin of -3,650.39%. Avidity Biosciences' return on equity of -44.92% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%
Kura Oncology	-411.19%	-141.95%	-43.28%

Kura Oncology has higher revenue and earnings than Avidity Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$36.68M	5.83	-$322.30M	N/A	N/A
Kura Oncology	$67.48M	12.12	-$278.67M	-$3.35	N/A

Summary

Avidity Biosciences and Kura Oncology tied by winning 7 of the 14 factors compared between the two stocks.

How does Avidity Biosciences compare to Sana Biotechnology?

Avidity Biosciences (NASDAQ:RNA) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Sana Biotechnology has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Avidity Biosciences' return on equity of -44.92% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%
Sana Biotechnology	N/A	-108.01%	-40.68%

Avidity Biosciences has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market.

88.2% of Sana Biotechnology shares are held by institutional investors. 3.8% of Avidity Biosciences shares are held by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Avidity Biosciences currently has a consensus target price of $70.29, suggesting a potential upside of 462.35%. Sana Biotechnology has a consensus target price of $9.50, suggesting a potential upside of 239.41%. Given Avidity Biosciences' higher probable upside, equities research analysts plainly believe Avidity Biosciences is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.33
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Sana Biotechnology has lower revenue, but higher earnings than Avidity Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$36.68M	5.83	-$322.30M	N/A	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

In the previous week, Sana Biotechnology had 2 more articles in the media than Avidity Biosciences. MarketBeat recorded 4 mentions for Sana Biotechnology and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.11 beat Sana Biotechnology's score of 0.47 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sana Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sana Biotechnology beats Avidity Biosciences on 8 of the 15 factors compared between the two stocks.

How does Avidity Biosciences compare to Evommune?

Evommune (NYSE:EVMN) and Avidity Biosciences (NASDAQ:RNA) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, Avidity Biosciences had 1 more articles in the media than Evommune. MarketBeat recorded 2 mentions for Avidity Biosciences and 1 mentions for Evommune. Avidity Biosciences' average media sentiment score of 1.11 beat Evommune's score of -0.35 indicating that Avidity Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avidity Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evommune has higher earnings, but lower revenue than Avidity Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	55.75	-$68.87M	-$9.50	N/A
Avidity Biosciences	$36.68M	5.83	-$322.30M	N/A	N/A

Evommune has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Evommune's return on equity of 0.00% beat Avidity Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%

Evommune presently has a consensus target price of $49.25, indicating a potential upside of 144.78%. Avidity Biosciences has a consensus target price of $70.29, indicating a potential upside of 462.35%. Given Avidity Biosciences' higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than Evommune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Evommune beats Avidity Biosciences on 9 of the 13 factors compared between the two stocks.

Get Avidity Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNA vs. The Competition

Export

Metric	Avidity Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$213.83M	$3.36B	$6.46B	$12.29B
Dividend Yield	N/A	2.25%	2.66%	5.66%
P/E Ratio	-2.52	19.73	23.95	24.47
Price / Sales	5.83	306.28	513.35	137.30
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	1.15	7.99	10.50	6.71
Net Income	-$322.30M	$23.89M	$3.56B	$337.21M
7 Day Performance	6.29%	0.44%	0.00%	1.92%
1 Month Performance	-5.52%	-0.89%	1.34%	3.80%
1 Year Performance	-58.05%	42.31%	23.68%	28.85%

Avidity Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNA Avidity Biosciences	2.4017 of 5 stars	$12.50 -2.0%	$70.29 +462.4%	-59.4%	$213.83M	$36.68M	N/A	190	Positive News
REPL Replimune Group	1.7726 of 5 stars	$8.97 -5.3%	$4.88 -45.7%	-8.4%	$781.96M	N/A	N/A	210	Positive News Upcoming Earnings
ORIC Oric Pharmaceuticals	2.626 of 5 stars	$7.53 +0.4%	$19.36 +157.2%	-12.8%	$776.38M	N/A	N/A	80
KURA Kura Oncology	3.4286 of 5 stars	$8.56 -2.1%	$25.58 +198.9%	+48.1%	$775.89M	$67.48M	N/A	130	Analyst Forecast Analyst Revision
SANA Sana Biotechnology	2.2347 of 5 stars	$2.69 +0.4%	$9.50 +253.2%	+10.0%	$745.82M	N/A	N/A	380	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNA) was last updated on 6/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avidity Biosciences (RNA) Competitors

RNA vs. REPL, ORIC, KURA, SANA, and EVMN

How does Avidity Biosciences compare to Replimune Group?

Summary

How does Avidity Biosciences compare to Oric Pharmaceuticals?

Summary

How does Avidity Biosciences compare to Kura Oncology?

Summary

How does Avidity Biosciences compare to Sana Biotechnology?

Summary

How does Avidity Biosciences compare to Evommune?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNA vs. The Competition

Avidity Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avidity Biosciences (RNA) Competitors

RNA vs. REPL, ORIC, KURA, SANA, and EVMN

How does Avidity Biosciences compare to Replimune Group?

Does the media refer more to RNA or REPL?

Is RNA or REPL more profitable?

Which has preferable valuation & earnings, RNA or REPL?

Do analysts recommend RNA or REPL?

Do insiders and institutionals have more ownership in RNA or REPL?

Which has more risk and volatility, RNA or REPL?

Summary

How does Avidity Biosciences compare to Oric Pharmaceuticals?

Do insiders & institutionals believe in RNA or ORIC?

Which has better earnings & valuation, RNA or ORIC?

Do analysts recommend RNA or ORIC?

Does the media refer more to RNA or ORIC?

Is RNA or ORIC more profitable?

Which has more risk & volatility, RNA or ORIC?

Summary

How does Avidity Biosciences compare to Kura Oncology?

Do analysts recommend RNA or KURA?

Which has more risk and volatility, RNA or KURA?

Does the media prefer RNA or KURA?

Is RNA or KURA more profitable?

Which has stronger valuation & earnings, RNA or KURA?

Summary

How does Avidity Biosciences compare to Sana Biotechnology?

Is RNA or SANA more profitable?

Which has more volatility and risk, RNA or SANA?

Do insiders & institutionals hold more shares of RNA or SANA?

Do analysts prefer RNA or SANA?

Which has better earnings and valuation, RNA or SANA?

Does the media favor RNA or SANA?

Summary

How does Avidity Biosciences compare to Evommune?

Does the media favor EVMN or RNA?

Which has better valuation & earnings, EVMN or RNA?

Is EVMN or RNA more profitable?

Do analysts prefer EVMN or RNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNA vs. The Competition

Avidity Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools